Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oswaldo Cruz Foundation (Fiocruz) is a leading institution of science and a public health in Latin America. The new online knowledge hub launched on 3rd December 2019 and feature virtual courses, information and news about the Foundation.

TGHN discussion panel

The Fiocruz Knowledge Hub is an online sharing space, which aims to strengthen networks and increase Fiocruz's international presence, contributing to improve regional and global public health research capacities.

Bonny Baker who leads The Global Health Network regional programs and Gustavo Matta Researcher and Coordinator of the Zika Social Sciences Network at Fiocruz introduced the Fiocruz Hub at the International Seminar of the Fiocruz Internationalization Program in Rio de Janeiro today.

Fiocruz's virtual space is the result of partnership signed on July between the Foundation and the University of Oxford, responsible for the Global Health Network. Fiocruz is the most prominent Institution of Science and Technology in Health in Latin America, with a large expertise in teaching and researching, and solid history of cooperation with Latin American and Portuguese speaking African countries.

With the new space, Fiocruz online courses will be available for The Global Health Network community. Fiocruz Virtual Campus have already qualified over 1.8 million Brazilian health professionals, in areas such as Yellow Fever, Zika, maternal care, public systems and others. The knowledge hub will also be updated with publications with the latest research results, as well as information and news about Fiocruz.

Similar stories

A new WWARN study supports safety of WHO recommended malaria treatment to advance elimination and reduce spread of artemisinin resistance

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Routine surveillance data can provide an early warning system for antimalarial resistance in pre-elimination areas in Africa

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

FORESFA and VIE project meetings

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.